Latest news with #SolsticeAir
Time of India
22-05-2025
- Health
- Time of India
Lupin introduces Honeywell Solstice Air inhalers for sustainable respiratory care
Representative image (Picture credit: X/@LupinGlobal) BENGALURU: Lupin is using Honeywell's Solstice Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants. Designed for patients with asthma and chronic obstructive pulmonary disease (COPD), Honeywell Solstice Air has the potential to prevent the release of high global warming potential (GWP) molecules, marking a major step forward in helping to reduce carbon emissions. Solstice Air offers an alternative to traditional hydrofluorocarbon (HFC)-based propellants, helping to reduce greenhouse gas emissions by up to 99.9%. ' By integrating Solstice Air in our products, we are not only enhancing patient care, but we are also significantly reducing environmental impact,' said Vinita Gupta, CEO Lupin. 'Solstice Air can play a critical role in ensuring that Lupin's respiratory inhalers provide safe and effective treatment options that also leverage the latest advancements in technology to reduce harmful greenhouse gas emissions,' said Ashish Modi, President of Honeywell India. 'By continuing to research and develop advanced technologies for reducing carbon, Honeywell is dedicated to driving innovation that enhances the efficacy of health solutions while pioneering emissions-reducing practices that support industry advancements. ' Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
New Indian Express
21-05-2025
- Health
- New Indian Express
Sustainable healthcare: Why Lupin-Honeywell partnership is significant
In India, pMDIs—particularly those using HFCs—are a significant source of greenhouse gas emissions due to the high GWP of these propellants. Although dry-powder inhalers (DPIs) are used more frequently, pMDIs contribute far more to emissions. Research shows that a large share of these emissions comes from short-acting beta-2 agonist (SABA) inhalers, especially when asthma is poorly controlled. According to Lupin, its new product is designed for patients with asthma and COPD. Honeywell's Solstice Air offers a low-GWP alternative that could substantially reduce the release of high-impact greenhouse gases, marking a major step forward in reducing the industry's carbon emissions. Technology to reduce harmful greenhouse gas emissions Lupin aims to become the first pharmaceutical company in India to use Honeywell's Solstice Air at scale as a next-generation propellant in pMDIs. Solstice Air provides an alternative to traditional HFC propellants, with the potential to cut greenhouse gas emissions by up to 99.9%. 'Lupin's partnership with Honeywell underscores our commitment to delivering high-quality medicines while working towards a healthier, more sustainable future for our patients and communities worldwide. By integrating Solstice Air into our products, we are not only enhancing patient care but also significantly reducing our environmental impact,' claimed Lupin CEO Vinita Gupta in a recent media statement. 'Solstice Air can play a critical role in ensuring that Lupin's respiratory inhalers provide safe and effective treatment options, while also leveraging the latest technology to reduce harmful greenhouse gas emissions,' added Ashish Modi, President, Honeywell India. 'By continuing to research and develop advanced technologies to reduce carbon emissions, Honeywell is committed to driving innovation that enhances healthcare efficacy while pioneering sustainable practices,' Modi claims.
Business Standard
20-05-2025
- Health
- Business Standard
Lupin to develop next-gen inhalers using Honeywell's Solstice Air propellant
Lupin announced today its plan to use Honeywell's Solstice Air (HFO-1234ze cGMP) propellant to transform respiratory care through the development of next-generation inhalers. Designed for patients with asthma and chronic obstructive pulmonary disease (COPD), Honeywell Solstice Air has the potential to prevent the release of high global warming potential (GWP) molecules, marking a major step forward in helping to reduce carbon emissions. Lupin intends to become the first pharmaceutical company in India to use Honeywell's Solstice Air product at scale as a next-generation propellant in pressurized metered-dose inhalers (pMDIs). Solstice Air offers an alternative to traditional hydrofluorocarbon (HFC)-based propellants, helping to reduce greenhouse gas emissions by up to 99.9%.1 By investigating the use of this innovative, non flammable propellant in its pMDIs, Lupin is taking a significant step toward minimizing the environmental impact of respiratory solutions while providing effective treatment options for patients with asthma and COPD. L
Time of India
20-05-2025
- Business
- Time of India
Lupin partners with Honeywell for usage of propellant for inhalers
Lupin Ltd partners with Honeywell to incorporate 'Solstice Air' propellant in next-generation inhalers for asthma and COPD, aiming to reduce carbon emissions. This collaboration makes Lupin the first Indian pharma company to use Solstice Air at scale in pressurized metered-dose inhalers (pMDIs). Solstice Air offers a sustainable alternative, reducing greenhouse gas emissions by up to 99.9%. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Pharma major Lupin Ltd on Tuesday said it has partnered with Honeywell to use the latter's propellant ' Solstice Air ' to transform respiratory care through the development of next-generation inhalers . Designed for patients with asthma and chronic obstructive pulmonary disease ( COPD ), Honeywell 's 'Solstice Air' has the potential to prevent the release of high global warming potential (GWP) molecules, marking a major step forward in helping to reduce carbon emissions, the company said in a statement. Lupin 's partnership with Honeywell underscores our commitment to delivering high-quality medicines while working towards a healthier, more sustainable future for our patients and communities worldwide. By integrating Solstice Air in our products, we are not only enhancing patient care, but we are also significantly reducing environmental impact ," Lupin CEO Vinita Gupta Energy and Sustainability Solutions Business President Jeff Dormo said,"Solstice Air can play a critical role in ensuring that Lupin life-saving devices provide safe and effective treatment options that also leverage the latest advancements in technology to reduce harmful greenhouse gas emissions ."Lupin said it intends to become the first pharmaceutical company in India to use Honeywell's Solstice Air product at scale as a next-generation propellant in pressurised metered-dose inhalers (pMDIs).Solstice Air offers an alternative to traditional hydrofluorocarbon (HFC)-based propellants, helping to reduce greenhouse gas emissions by up to 99.9 per cent, it added."By investigating the use of this innovative, nonflammable propellant in its pMDIs, Lupin is taking a significant step toward minimizing the environmental impact of respiratory solutions while providing effective treatment options for patients with asthma and COPD," the company terms of the deal are subject to negotiation and execution of definitive documents acceptable to both Honeywell and Lupin, it added.
Malaysian Reserve
20-05-2025
- Business
- Malaysian Reserve
Lupin and Honeywell Move Forward Jointly with Plans for HFO Technology in Inhalers
Lupin is set to become first Indian company to fully integrate Honeywell's Solstice® Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: (BLOOMBERG: LPCIN) NEW DELHI and MUMBAI, India, May 20, 2025 /PRNewswire/ — Global pharma major Lupin Limited (Lupin) announced today its plan to use Honeywell's Solstice® Air (HFO-1234ze cGMP) propellant to transform respiratory care through the development of next-generation inhalers. Designed for patients with asthma and chronic obstructive pulmonary disease (COPD), Honeywell Solstice Air has the potential to prevent the release of high global warming potential (GWP) molecules, marking a major step forward in helping to reduce carbon emissions. Lupin intends to become the first pharmaceutical company in India to use Honeywell's Solstice Air product at scale as a next-generation propellant in pressurized metered-dose inhalers (pMDIs). Solstice Air offers an alternative to traditional hydrofluorocarbon (HFC)-based propellants, helping to reduce greenhouse gas emissions by up to 99.9%.1 By investigating the use of this innovative, non-flammable propellant in its pMDIs, Lupin is taking a significant step toward minimizing the environmental impact of respiratory solutions while providing effective treatment options for patients with asthma and COPD. 'Lupin's partnership with Honeywell underscores our commitment to delivering high-quality medicines while working towards a healthier, more sustainable future for our patients and communities worldwide. By integrating Solstice Air in our products, we are not only enhancing patient care, but we are also significantly reducing environmental impact,' said Vinita Gupta, CEO, Lupin. 'Solstice Air can play a critical role in ensuring that Lupin life-saving devices provide safe and effective treatment options that also leverage the latest advancements in technology to reduce harmful greenhouse gas emissions,' said Jeff Dormo, a president in Honeywell's Energy and Sustainability Solutions business. 'By continuing to research and develop advanced technologies for reducing carbon, Honeywell is dedicated to driving innovation that enhances the efficacy of health solutions while pioneering emissions reducing practices that support industry advancements.' The terms of the deal are subject to negotiation and execution of definitive documents acceptable to both Honeywell and Lupin. References: 1Studies conducted by UNEP and American Lung Association About Lupin Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. To know more, visit or follow us on LinkedIn About Honeywell Honeywell is an integrated operating company serving a broad range of industries and geographies around the world. Our business is aligned with three powerful megatrends – automation, the future of aviation and energy transition – underpinned by our Honeywell Accelerator operating system and Honeywell Forge IoT platform. As a trusted partner, we help organizations solve the world's toughest, most complex challenges, providing actionable solutions and innovations through our Aerospace Technologies, Industrial Automation, Building Automation and Energy and Sustainability Solutions business segments that help make the world smarter and safer as well as more secure and sustainable. For more news and information on Honeywell, please visit Solstice® is the registered trademark of Honeywell International Inc. Logo: View original content:
